News stories about ObsEva (NASDAQ:OBSV) have been trending positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ObsEva earned a news sentiment score of 0.32 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.6864766849869 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
OBSV has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of ObsEva in a research report on Monday, February 5th. Leerink Swann boosted their price objective on shares of ObsEva from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $18.00 price objective (up from $16.00) on shares of ObsEva in a research report on Tuesday, February 27th. BMO Capital Markets reaffirmed a “buy” rating and issued a $24.00 price objective on shares of ObsEva in a research report on Tuesday, February 27th. Finally, Zacks Investment Research cut shares of ObsEva from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.00.
Shares of OBSV stock opened at $12.60 on Friday. ObsEva has a 1 year low of $5.00 and a 1 year high of $15.81. The firm has a market capitalization of $454.49 million, a price-to-earnings ratio of -5.60 and a beta of 2.82.
ObsEva (NASDAQ:OBSV) last issued its quarterly earnings results on Friday, March 9th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.08. equities research analysts anticipate that ObsEva will post -1.92 earnings per share for the current fiscal year.
ObsEva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.